The large study analyzed the health records of 1.3 million people.
Boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, is seen at a Rock Canyon Pharmacy in Provo, Utah, March 29, 2023.suggests that GLP-1 agonist medications like Ozempic, which are used for diabetes management and weight loss, may help reduce the risk of overdose and alcohol intoxication in people with substance use disorders.The large study, published in the journal, Addiction, analyzed the health records of 1.3 million people from 136 U.S.
The protective effects were consistent and even applied to people with Type 2 diabetes, obesity, or both conditions."As clinicians, recognizing that people can get double benefits from something is always helpful and as more obesity medications enter the market, this can help personalize treatments," she said.
The Addiction study does not prove that GLP-1 medications directly lower the risks of opioid overdose and alcohol intoxication, only that people taking them seemed to be helped. And it only included hospitalizations so it's not clear if they will work as well in less serious cases.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Women May Lose More Weight on Ozempic, Other Semaglutides, New Study FindsA new study published in JAMA Network Open contends that women may lose more weight on semaglutides like Ozempic than men. Here's why, according to doctors.
Read more »
WeightWatchers CEO suddenly quits after push to embrace weight-loss drugs like Ozempic, WegovySima Sistani, who took up the CEO post at WW International two-and-a-half years ago, is out, according to the company.
Read more »
Bernie Sanders grills Novo Nordisk CEO on price of Ozempic, other weight-loss drugsSen. Bernie Sanders grilled Novo Nordisk's CEO Lars Jorgensen over the cost of the company's weight loss and diabetes medications, Ozempic and Wegovy.
Read more »
Novo Nordisk CEO Grilled Over High Prices of Weight-Loss Drugs Ozempic and WegovyDuring a Congressional hearing, Novo Nordisk CEO Lars Jorgensen faced pressure from lawmakers regarding the high prices of weight-loss drugs Ozempic and Wegovy. While Jorgensen attributed some costs to pharmacy benefit managers, he agreed to meet with them to discuss potential price reductions.
Read more »
Ozempic, Wegovy maker Novo Nordisk faces hearing over high cost of weight loss drugsBlockbuster drugs Ozempic and Wegovy have sparked conversation and changed weight loss worldwide. In an exclusive interview, NBC News’ Megan Fitzgerald sits down with Novo Nordisk CEO Lars Fruergaard Jørgensen who helmed it all, and presses him on the high price, drug shortages, and long-term effects.
Read more »
Maker of Ozempic and Wegovy faces grilling over high cost of weight loss drugsIs Novo Nordisk helping Americans save taxpayer money or ripping them off? The company's CEO is scheduled to testify Tuesday on Capitol Hill.
Read more »